Trial reportThe New England journal of medicine2012
Prostate-cancer mortality at 11 years of follow-up.
Trial report in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 478 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial To Assess and Compare the Outcomes of 20-core Versus 12-core Prostate Biopsy
Evaluation of An Online Intervention In Improving General Practitioners' Practice In Prostate Cancer Screening
Who cites it
478 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,231 citations in OpenAlex.
- Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.BJU international · 2025Pooled it
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.The Journal of urology · 2023Guideline
- Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature.Nutrients · 2021Pooled it
- Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.The oncologist · 2021Pooled it
- Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Influence of Regular Statin Intake on Prostate-Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau).Cancer medicine · 2025Trial
- Trial
- Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.European urology · 2023Trial
- Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.JAMA oncology · 2022Trial
- Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.Lancet (London, England) · 2021Trial
- Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.The British journal of general practice : the journal of the Royal College of General Practitioners · 2021Trial
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.European urology · 2019Trial
- Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?PloS one · 2019Trial
- Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.PloS one · 2019Trial
- Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.PloS one · 2019Trial
- Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.Scandinavian journal of urology · 2018Trial
- Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.Journal of medical screening · 2017Trial
- Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.Cancer · 2017Trial
418 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
30 authors at 14 institutions in 10 countries.
Funding
Abstract
backgroundSeveral trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up.
methodsThe study involved 182,160 men between the ages of 50 and 74 years at entry, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were offered PSA-based screening, whereas those in the control group were not offered such screening. The primary outcome was mortality from prostate cancer.
resultsAfter a median follow-up of 11 years in the core age group, the relative reduction in the risk of death from prostate cancer in the screening group was 21% (rate ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.001), and 29% after adjustment for noncompliance. The absolute reduction in mortality in the screening group was 0.10 deaths per 1000 person-years or 1.07 deaths per 1000 men who underwent randomization. The rate ratio for death from prostate cancer during follow-up years 10 and 11 was 0.62 (95% CI, 0.45 to 0.85; P=0.003). To prevent one death from prostate cancer at 11 years of follow-up, 1055 men would need to be invited for screening and 37 cancers would need to be detected. There was no significant between-group difference in all-cause mortality.
conclusionsAnalyses after 2 additional years of follow-up consolidated our previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality. (Current Controlled Trials number, ISRCTN49127736.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.